Anúncio
Anúncio

CTKB

CTKB logo

Cytek Biosciences, Inc. Common Stock

5.45
USD
Patrocinado
+0.02
+0.28%
09 de jan., 15:58 UTC -5
Encerrado
exchange

Pós-Mercado

5.57

+0.13
+2.37%

Relatórios de Lucros CTKB

Rácio de surpresa positiva

CTKB separação 10 de 18 últimas estimativas.

56%

Próximo Relatório

Em 4 Dias
Data do Próximo Relatório
15 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$58.07M
/
-$0.03
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+11.04%
/
-25.00%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+1.03%
/
-142.86%

Cytek Biosciences, Inc. Common Stock earnings per share and revenue

On 05 de nov. de 2025, CTKB reported earnings of -0.04 USD per share (EPS) for Q3 25, beating the estimate of -0.05 USD, resulting in a 25.37% surprise. Revenue reached 52.29 milhão, compared to an expected 52.52 milhão, with a -0.43% difference. The market reacted with a +13.22% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analistas forecast an EPS of -0.03 USD, with revenue projected to reach 58.07 milhão USD, implying an diminuir of -25.00% EPS, and aumentar of 11.04% in Revenue from the last quarter.
FAQ
For Q3 2025, Cytek Biosciences, Inc. Common Stock reported EPS of -$0.04, beating estimates by 25.37%, and revenue of $52.29M, -0.43% below expectations.
The stock price moved up 13.22%, changed from $4.01 before the earnings release to $4.54 the day after.
The next earning report is scheduled for 15 de jan. de 2026.
Based on 7 analistas, Cytek Biosciences, Inc. Common Stock is expected to report EPS of -$0.03 and revenue of $58.07M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio